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A comparison of clinically useful phosphorus binders for pa-
tients with chronic kidney failure. Over the past 30 years it
has become apparent that hyperphosphatemia plays a major
causative role across the entire spectrum of morbidity associ-
ated with advancing kidney dysfunction and failure. A large
fraction (60% to 70%) of dietary phosphorus is absorbed and
normally excreted by the kidneys. Ideally, as kidney function
deteriorates, the net quantity of phosphorus absorbed from the
GI tract should be proportionally reduced to match the decrease
in kidney function. After initiation of chronic dialysis therapy,
the absorbed phosphorus load should match the amount of
phosphorus removed via dialysis plus any excreted by residual
kidney function. Because it is very difficult to reduce dietary
phosphorus to these levels, a variety of oral phosphorus binders
have been employed. Currently available binders include alka-
line aluminum, magnesium, and calcium salts (primarily cal-
cium carbonate and calcium acetate), various iron salts, and the
binding resin sevelamer hydrochloride. Lanthanum carbonate
is the newest agent and will probably be released shortly. This
review compares the theoretic and in vitro chemistry of these
drugs with in vivo data obtained in both normal patients, and in
patients with kidney failure. The clinical potency and potential
toxicity of the binding agents are compared, and optimal drug
administration strategies are also reviewed.
The average daily phosphorous intake of North Amer-
ican or European adults is about 1000 mg in women and
1500 mg in men [1]. Between 60% and 70% of ingested
phosphorus is absorbed in the small bowel (primarily
in the duodenum and jejunum). In normal adults, aver-
age daily urinary phosphorus excretion equals the net
phosphorus absorption by the gastrointestinal (GI) tract.
Phosphorus balance is positive in growing children and
pregnant women due to increases in body, and or fetal,
mass.
The kidney normally filters large amounts of inorganic
phosphorus and then reabsorbs >90% of this load in the
tubules, so that excretion is less than 10% of the filtered
load. Early kidney dysfunction and reduced glomerular
filtration decreases the filtered load of phosphorus, but
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tubule reabsorption of phosphorus also decreases so that
urinary phosphorus excretion continues to match GI ab-
sorption. This compensating reaction is largely because of
secondary hyperparathyroidism–increased parathyroid
hormone (PTH) levels marked reduce renal tubule phos-
phorus reabsorption. Equality between phosphorus input
and output, with only slight changes in serum inorganic
phosphorus concentration, may be maintained for a pe-
riod of time. However, as renal function deteriorates fur-
ther, homeostatic mechanisms fail, phosphorus balance
becomes positive, and progressive hyperphosphatemia
usually develops.
The association of hyperphosphatemia and kidney dys-
function has been known for over 80 years [2], Al(OH)2
was used to reduce phosphorus levels and heal uremic
bone disease in 1941 [3], and metastatic calcification has
been attributed to hyperphosphatemia since the early
1960s [4]. However, the clinical impact and toxicity of
hyperphosphatemia was not widely emphasized until the
groundbreaking studies carried out in the early 1970s
by Bricker et al [5, 6]. Using animal models, they de-
lineated the pathophysiologic cascade triggered by hy-
perphosphatemia, leading to hypocalcemia, secondary
hyperparathyroidism, reduced 1,25vitD3, and progres-
sive metabolic bone disease. These studies also trig-
gered efforts by clinicians to aggressively attempt control
of phosphorous levels in patients with advancing and
end-stage kidney disease. The population at risk also
increased markedly as hemodialysis became a widely
available treatment. Phosphorus control strategies in-
cluded dietary phosphorus restriction, the ingestion of
drugs that bind phosphorus within the GI tract and
thereby reduce its absorption, and phosphorus removal
with dialysis.
A four-hour hemodialysis treatment may remove
about 1000 mg of phosphorus, but this is generally inad-
equate to restore normal phosphorus levels and phos-
phorus balance (with the exception of slow, daily, and/or
nocturnal hemodialysis, which removes much greater
quantities of phosphorus) [7–9]. Therefore, re-
establishment of normal phosphorus levels and balance
requires a major reduction in phosphorus absorption.
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Fig. 1. A theoretical analysis of the effect of pH on the binding of phos-
phorus by dissolved calcium or aluminum at equilibrium. Aluminum
binds virtually all the phosphorus regardless of pH, while calcium bind-
ing is seen to be much better above pH 5. Initial concentrations: phos-
phorus 320 mg/600 mL, calcium or aluminum 75 mEq/600 mL. Adapted
from Sheikh et al [12].
This can only be partially accomplished by dietary re-
striction because most foods contain abundant amounts
of phosphorus. Consequently, various phosphorus-
binding compounds are usually required to normalize
phosphorus levels and balance.
The history of phosphorus binders can be generally di-
vided into three overlapping eras. The first began in the
early 1970s, when the importance of phosphorus control
was first emphasized, and was characterized by the perva-
sive use of alkaline aluminum salts. This continued until
the early 1980s, when the toxicity of aluminium became
widely recognized [10, 11]. The second, the era of cal-
cium salts, started in the early 1980s and has continued
through the present time. We are currently in the third
phosphorus binder era, represented by introduction of
nonmetallic phosphorus binding resins and other novel
agents.
Most clinically useful phosphorus binders are hydrox-
ide, carbonate, or acetate salts of metal ions, such as alu-
minum, calcium, magnesium, and lanthanum. pH affects
both the rate of dissolution of the salt and the subsequent
binding reaction between the metal ion and phosphate.
Generally, a very acidic pH is best to dissolve and ion-
ize the salt. Then, the metal ion must combine with in-
organic phosphorus (phosphate), and this reaction may
also be pH dependent. The optimal pH for these two re-
action steps may be very different. For example, calcium
carbonate is most soluble at pH 1 to 3, but calcium to
phosphate binding is optimal above pH 5.
ALUMINUM AND CALCIUM SALT
PHOSPHORUS BINDERS
Figure 1 shows the theoretical effect of pH on phos-
phorus binding by aluminum and calcium. These calcu-
lations assume that 320 mg of phosphorus, as sodium
phosphate, is dissolved in 600 mL of fluid (to approximate
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Fig. 2. In vitro phosphorous binding by aluminum hydroxide gel—the
effect of pH and time. Aluminum hydroxide gel was added to a beaker
containing dissolved phosphate maintained in a shaker bath at 37◦C.
The pH was adjusted with HCl or NaOH as needed to maintain a
constant level. Initial concentrations: phosphorus 320 mg/600 mL, alu-
minum 75 mEq/600 mL. Adapted from Sheikh et al [12].
the phosphorus content and volume of an average meal),
and then mixed with 75 mEq of a very soluble aluminum
or calcium salt. Under these conditions, aluminum com-
pletely binds the phosphorus, and this reaction is pH inde-
pendent [12]. However, theoretical calcium-phosphorus
binding has major pH dependency, with virtually no bind-
ing below pH 3.5, and maximal binding above pH 5. The
pH effect on binding between calcium and phosphorus is
related to the precipitation constants of various calcium-
phosphate compounds and the relative concentrations of
H3PO4, H2PO4−1, HPO4−2, and PO4−3 in the solution
at any given pH. The theoretical calculations in Figure
1 assume that all of the aluminum or calcium is initially
dissolved and ionized.
Aluminum salts
Figure 2 shows the results of comparable in vitro exper-
iments using identical concentrations of phosphorus and
aluminum salts [12]. Aluminum chloride, a very soluble
and reactive salt, binds phosphorus with near theoreti-
cal potency, and binding is relatively independent of pH.
However, aluminum chloride is very corrosive, generat-
ing HCl when dissolved in water, and therefore cannot
be utilized clinically. Alkaline aluminum salts includ-
ing aluminum hydroxide gel (Amphojel) or aluminum
carbonate (Basaljel) (both manufactured by Wyeth
Laboratories, Collegeville, PA, USA) are well tolerated
(at least acutely; see below), and have been used as
antacids for many decades. To the extent these salts
dissolve and release aluminum ions, they are potent
phosphorus binders. However, as shown in Figure 2, phos-
phorus binding by aluminum hydroxide after 1 to 24 hours
was only about 30% to 60% of the theoretical predic-
tions. The difference is due to slow dissolution and ion-
ization of the alkaline aluminum salt. Under these condi-
tions, phosphorus binding is pH dependent with greater
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binding in a more acid environment. This occurs be-
cause an acid pH is necessary to dissolve the salt and
release aluminum ions to bind phosphorus. Similar re-
sults (not shown) were seen with aluminum carbonate gel
(Basaljel) and sucralfate (Carafate; Hoechst Marion
Roussel, Kansas City, MO, USA) [12]. Other aluminum
salts commercially available in the United States, includ-
ing ALternaGEL (Johnson & Johnson, New Brunswick,
NJ, USA) and Alu-Caps (3M, St. Paul, MN, USA), have
similar properties.
The effect of aluminum salts on phosphorus absorp-
tion was then studied in vivo in normal subjects us-
ing a well-characterized GI washout methodology [12].
These studies demonstrated that aluminum carbonate gel
(Basaljel) reduced the absorption of dietary phospho-
rus from 66% (263 mg of the 345 mg of phosphorus in
the meal) to 18% (61 mg of the 345 mg in the meal), con-
firming the clinical impression that alkaline aluminum
salts were very effective GI phosphorus binders. In dial-
ysis patients, aluminum salts reduced dietary phospho-
rus absorption from 70% to between 35% and 49% [13].
Presumably, the salts dissolve in the stomach and the alu-
minum ions then bind phosphate released from the food
in the stomach and small bowel.
Despite the relative potency of aluminum salts, phos-
phorus control remained suboptimal for most patients.
The large doses required with each meal, the taste,
and resulting constipation produced poor medication
compliance (even though these drugs were relatively
inexpensive). Dietary indiscretion, use of vitamin D
preparations that increase GI phosphorous absorption,
and endogenous release of phosphorous from bone
caused by secondary hyperparathyroidism also con-
tributed to persisting hyperphosphatemia. Nonetheless,
aluminum salts were, and probably still are, the most po-
tent phosphorus binders available for clinical use. Unfor-
tunately, the suspicion that aluminum salts might be toxic,
first seriously raised in the early 1970s [14, 15], was proven
correct [10, 11]. A tiny fraction of the ingested aluminum
load is absorbed. With normal kidney function most of the
absorbed aluminum is excreted. However, when dialysis
patients ingest large quantities of these salts, aluminum
accumulates in and damages the skeleton, central ner-
vous system, peripheral nerves, parathyroid tissue, and
hematopoietic cells. Progressive and often fatal, skeletal
and neurologic dysfunction were the most devastating
manifestations of this poisoning. The disease was partic-
ularly severe in centers using dialysate contaminated with
high levels of aluminum from municipal water supplies.
The relative importance of aluminum loading from the
dialysate and from ingested medications varied from cen-
ter to center and among different populations of patients
with kidney disease [10, 11]. However, even patients not
on dialysis can accumulate toxic levels of aluminum when
high doses are ingested, especially if citrate salts, which
increase aluminum absorption, are also ingested [16].
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Fig. 3. In vitro phosphorus binding by calcium carbonate—the effect
of pH and time. Calcium carbonate was added to a beaker containing
dissolved phosphate maintained in a shaker bath at 37◦C. The pH was
adjusted with HCl or NaOH as needed to maintain a constant level.
Initial concentrations: phosphorus 320 mg/600 mL, calcium 75 mEq/600
mL. Adapted from Sheikh et al [12].
Calcium salts
By the early 1980s, nephrologists were aggressively
seeking alternative, non-aluminum, phosphorus binders.
This ushered in the next phosphorus-binding era, domi-
nated by the calcium salts. It had been known for decades
that calcium salts bind dietary phosphorus, albeit less
effectively than aluminum [17]. There are at least two
reasons that calcium salts are less effective phosphorus
binders than aluminum salts. First, unlike ionized alu-
minum, ionized calcium binding to phosphorus is very
pH dependent and decreases sharply below pH 5 (Fig. 1).
Simultaneously, calcium carbonate, the most widely used
calcium salt, dissolves best in a very acid milieu. Thus,
a major problem with calcium carbonate is the opposite
effect of pH on solubility and on the calcium-phosphate
reaction. Acidity is best for solubility, but binding to phos-
phorus is best at higher pH. After one hour, in vitro
phosphorus binding by calcium carbonate is minimal as a
result of the salt’s insolubility (Fig. 3). After four hours, in
vitro binding has improved, but only around pH 5; bind-
ing falls sharply above pH 5 (due to less dissolution of the
salt) and below pH 5 (due to less precipitation of calcium
with phosphorus) (Fig. 3). Theoretical maximal binding
at any pH is not achieved for several days. Therefore, an
acid gastric pH is optimal to dissolve calcium carbonate,
but a higher pH is needed for the dissolved calcium to
bind phosphorus. Further, this data suggests that hypo-
or achlorhydria caused by gastritis, common among pa-
tients with kidney failure [18], or the use of H2 blockers
or proton pump inhibitors would compromise calcium
carbonate dissolution and reduce its efficacy as a phos-
phorus binder (this may also be true for aluminum salts).
Studies addressing this issue in patients report conflicting
conclusions [19, 20].
S-28 Emmett: Comparison of clinically useful phosphorus binders in CKD patients
400
350
300
250
200
150
100
50
0
Ph
os
ph
or
u
s 
a
bs
or
be
d,
 m
g
Placebo CaCO3 CaAcetate Aluminum
77%
44%
26%
18%
Intake
Meal phosphorous = 345 mg
Ca or aluminum = 50 mEq
Fig. 4. The effect of ingestion of calcium carbonate, calcium acetate, or
aluminum hydroxide gel on the absorption of ingested phosphorus by
normal subjects (N = 10). Absorption was measured with a one-meal
balance technique. The dose of each medication contained 50 mEq of
the metal. The numbers above each bar represent the percentage of
ingested phosphorus that is absorbed. Adapted from Sheikh et al [12].
In vivo studies showed that calcium carbonate bound
phosphorus only about half as well as equi-equivalent
doses of aluminum salts (Fig. 4) [12]. Despite these disad-
vantages, calcium carbonate use as a phosphorus binder
expanded rapidly because of the increasingly recognized
dangers of aluminum toxicity and the lack of better alter-
natives. However, very high doses of calcium carbonate,
averaging >8 to 10 g/day CaCO3 (3.2 to 4.0 g elemen-
tal calcium), and more than 17 g/day CaCO3 in some
patients, were required to control phosphorus levels [21,
22]. Calcium absorption increases with increasing dietary
intake, so these very high calcium doses undoubtedly pro-
duced positive calcium balance [23]. Depending on the
definition used, hypercalcemia developed in up to one
third of dialysis patients treated with high-dose calcium
carbonate [21, 22, 24, 25]. It generally resolved quickly
when the calcium dose was reduced. To some degree,
hypercalcemia could be avoided by reducing dialysate
bath calcium concentrations (i.e., to 2.5 mEq/L) [21, 24].
However, the simultaneous use of parenteral or oral vi-
tamin D preparations to suppress parathyroid secretion
increased GI calcium absorption and the frequency of
hypercalcemia.
The search for safer and more effective phosphorus-
binding calcium salts led to the introduction of calcium ac-
etate (PhosLo; Nabi Biopharmaceuticals, Boca Raton,
FL, USA) in 1991 [26]. Calcium acetate is 10,000 times
more soluble than calcium carbonate in water [12].
Figure 5 shows that in vitro calcium acetate binding
of phosphorus approximates the theoretical calcium-
phosphorus binding curve within one hour when calcium
carbonate binding of phosphorus remains poor. Short-
term balance studies in normal subjects and hemodialysis
patients showed that a given dose of elemental calcium
administered as calcium acetate bound twice as much
phosphorus as the same dose of calcium given as cal-
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Fig. 5. In vitro phosphorus binding by calcium acetate and calcium
carbonate—the effect of pH and time. The calcium salts were added to
a beaker containing dissolved phosphate maintained in a shaker bath at
37◦C. The pH was adjusted with HCl or NaOH as needed to maintain
a constant level. Initial concentrations: phosphorus 320 mg/600 mL,
calcium 75 mEq/600 mL, Adapted from Sheikh et al [12].
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cium carbonate (Fig. 4) [12, 27]. Multiple long-term large
studies of serum phosphorus control in dialysis patients
confirmed that half as much elemental calcium is required
for phosphorus binding when the acetate salt is used com-
pared with the carbonate salt [26, 28–32].
Short-term studies also indicated that when equal
amounts of elemental calcium were given as either cal-
cium acetate or calcium carbonate, the acetate salt bound
much more phosphate, and simultaneously significantly
less calcium was absorbed (Fig. 6) [12, 27]. The ratio of mg
phosphorus-bound/mEq calcium absorbed with calcium
acetate was 6.8 compared with 2.5 with calcium carbon-
ate. In other words, more calcium binding to phosphorus
means less is available to be absorbed. Therefore, if half
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as much calcium could be administered as the acetate
salt, it was predicted that less than half as much calcium
would be absorbed. If true, this finding would be of critical
importance in reducing excess calcium absorption when
patients chronically use calcium salts. Unfortunately, the
only clinical correlate of calcium absorption that has been
studied in long-term comparative human trials is the aver-
age serum calcium concentration and the frequency of hy-
percalcemia. Although some reported a lower frequency
of hypercalcemia with the calcium acetate [30, 31], others
found no difference [28, 29, 32]. However, calcium con-
centration and the frequency of hypercalcemia are very
indirect indices of calcium absorption or calcium balance.
The release of calcium from the skeleton, skeletal buffer-
ing of exogenous calcium, bone turnover rate, PTH sta-
tus, and vitamin D levels are just several factors which
affect blood calcium concentration independently of net
calcium balance. Some suggest that bone turnover rate
may have a greater effect on the development of hyper-
calcemia in dialysis patients than the oral calcium dose
[33].
Other calcium salts including citrate (Citracal;
Mission Pharmacal, Boerne, TX, USA), lactate, glu-
conate, and essential ketoacid analogues have been stud-
ied as potential phosphorus binders [34–38]. None of
these have proven to have a significant advantage over
calcium carbonate or acetate. Calcium citrate (Citracal)
is a particularly poor phosphorus binder because the cit-
rate anion competes with phosphorus for binding to cal-
cium [12] (this property of citrate is essential to maintain
calcium solubility in urine and reduce the risk of calcium
oxalate stones). Furthermore, as mentioned above, solu-
ble citrate salts markedly increase GI absorption of trace
elements, including aluminum, and thereby greatly ele-
vate the risk of aluminum toxicity if any aluminum salts
are also ingested [11, 39].
It is clear that calcium-based phosphorus binders
should be ingested together with, or in close temporal
proximity to each meal [40]. This strategy maximizes
binding of the calcium to dietary phosphorus, and simul-
taneously minimizes calcium absorption (Fig. 7) [40, 41].
In addition, patients should attempt to tailor each frac-
tional dose of phosphorus binder in proportion to the
estimated phosphorus load of each meal [22]. Although
these principles have only been well documented for cal-
cium salts, extrapolation to other phosphorus binders is
probably appropriate.
The use of any calcium salt in high doses to control
serum phosphorus in dialysis patients undoubtedly re-
sults in positive calcium balance (i.e., the absorbed cal-
cium load exceeds urine + dialysis calcium losses), and
this issue has recently become a point of major concern
and debate.
Cardiovascular mortality accounts for about 50% of
deaths occurring among dialysis patients [42]. Epidemi-
ologic studies show strong independent correlations be-
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tween risk of death and either hyperphosphatemia or a
high calcium-phosphorus product [43, 44]. Recent stud-
ies have also noted that dialysis patients, including very
young patients, have a high rate of peripheral and coro-
nary vascular calcification and cardiac valvular calcifica-
tion [45–50]. While it seems clear that these calcifications
are associated with high risk for cardiovascular disease
and death, it remains unknown if these vascular calci-
fications are the cause of disease or merely markers of
disease. Further, it is not known if increased GI calcium
absorption is the cause of the calcifications or if it directly
increases cardiovascular risk. High-dose calcium salt in-
gestion and high serum calcium concentrations have also
been linked to excessive parathyroid suppression and an
increasing frequency of adynamic bone disease [51, 52].
All of this has fueled significant concerns about the posi-
tive calcium balance that must develop when large doses
of calcium salts are ingested, and the effort to minimize
calcium absorption and seek non-aluminum, non-calcium
phosphorus binder alternatives.
NON-ALUMINUM, NON-CALCIUM PHOSPHATE
BINDERS
Magnesium salts
Both magnesium hydroxide and magnesium carbonate
have been studied, and although neither is particularly
effective, the carbonate salt is the better phosphorus-
binding agent [53–55]. Magnesium salts have two major
side effects. First, large amounts of magnesium can be
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absorbed and will produce hypermagnesemia. For pa-
tients on dialysis, this problem can be ameliorated by
reducing or eliminating the dialysate magnesium. Fre-
quent monitoring of blood magnesium levels is required.
Equally troubling and difficult to treat or prevent is the
diarrhea produced by virtually all magnesium salts when
large doses are ingested.
Lanthanum salts
Salts of the rare earth metals lanthanum and zirco-
nium are potentially excellent phosphorus binders, but
long-term safety remains of great concern. The chloride
salts are toxic but the carbonate salts are better tolerated
[56, 57]. Nonetheless, it is likely that small amounts of
these metals will be absorbed, and may, when ingested
chronically, accumulate and generate toxicity. Several
different lanthanum carbonate formulations are being
investigated, and FosrenolTM (Shire Pharmaceuticals,
Rockville, MD, USA) is in the final stages of FDA ap-
proval. Studies thus far have shown this to be an effec-
tive and well tolerated medication. Long-term efficacy
and safety studies and cost will be of critical importance
in determining the niche this drug will fill among the phos-
phorus binders.
Iron salts
Numerous ionic and non-ionic iron salts and iron-
carbohydrate complexes that have phosphorus-binding
properties have been studied in animal models and in
small-scale human trials. Although several have clin-
ical potential, none have yet been studied in large
numbers of patients, none are approved phosphorus
binders, and they are not generally used for this purpose
[58–61].
Sevelamer hydrochloride
We have now entered the third phosphorus binder era:
binders entirely free of any potentially toxic metals. The
first such agent to be marketed is sevelamer hydrochlo-
ride (RenaGel; Genzyme, Cambridge, MA, USA). This
cross-linked poly (allylamine HCl) exchange resin binds
phosphate and releases chloride. Phosphorus binding is
most effective in the pH range between 5 and 7 [62, 63]. As
noted, its major advantage is the absence of absorbable
metal cations. The drug also has an unanticipated benefi-
cial side effect of binding bile salts, and thereby reducing
LDL cholesterol levels [64–66]. Renagel also has sev-
eral drawbacks. It is very expensive (>$1.00/tablet, or
about $2,500/year when a relatively low dose of 6 tablets
are used/day), large quantities are generally required to
achieve control (5 to 7 g or 6 to 18 tablets/day, depending
on the tablet size), high doses generate GI complaints,
although probably not more frequently than from high-
dose calcium salts [67], and although no metal is released,
some of the chloride released when the resin binds phos-
phate (or HCO3) is absorbed together with a proton, and
this creates or worsens metabolic acidosis [67, 68]. Several
trials comparing RenaGel with calcium acetate suggest
the dose of each drug required for phosphorus control
translated to similar medication weight, but phosphorus
levels were generally lower with the calcium salt [67–70].
A randomized, double-blind comparison between cal-
cium acetate and Renagel (the dose of each drug was
titrated by the “blinded” physician to attempt adequate
phosphorus control) found the calcium salt controlled
phosphorus more effectively, and was more likely to pro-
duce acceptable phosphorus levels [67]. As expected, the
calcium levels were significantly higher with calcium ac-
etate, but because of a greater degree of phosphorus
reduction, calcium acetate therapy reduced the calcium-
phosphorus product below the level achieved with
than RenaGel (Fig. 8) [67]. Another study comparing
Renagel with calcium salts (both carbonate and acetate)
reported that coronary and aortic calcification, measured
with electron beam tomography, progressed more rapidly
in the calcium treated group [71]. However, due to a
number of methodologic concerns, including nonblind-
ing of the study drug, the divergent effects of calcium
salts and Renagel on LDL, the variety of calcium salts
used, dialysate calcium concentrations controlled, and a
large number of patient dropouts, the interpretation of
these results are controversial and await confirmation by
better controlled and longer duration studies. It is likely
that other more effective, well-tolerated, nontoxic, and
hopefully, less expensive phosphorus binders will be in-
troduced over the next few years.
Inhibition of transmucosal phosphorous transport
Another approach, not yet proven to be clinically ef-
fective or practical, is inhibition of the small intestinal
Na-phosphate transporter. Niceritrol, a nicotinic acid
prodrug marketed as a lipid-lowering drug, will re-
duce the activity of this transporter in rodents and has
shown some efficacy in a small preliminary human trial
[72, 73].
Finally, until we have much more effective and inexpen-
sive methods to reduce phosphorus absorption, the im-
portance of dietary phosphorus restriction should not be
neglected. At this time, a major reduction in phosphorus
intake adversely affects dietary palatability, and also may
require significant protein restriction. However, avoid-
ance of foods which are very rich in phosphorus, such as
dairy products, some carbonated drinks, processed meats,
nuts, and some baking powders remains important for
most patients with chronic kidney disease.
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